Asian setback for NicOx in Pfizer collaboration
This article was originally published in Scrip
Executive Summary
There has been more bad news for NicOx's glaucoma research alliance with Pfizerafter the US firm decided not to pursue the Asian Phase III development of the lead compound in the programme, PF-03187207.